Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
24
LENZ Quote, Financials, Valuation and Earnings
Last price:
$27.85
Seasonality move
:
-9.52%
Day range:
$27.65 - $29.02
52-week range:
$16.54 - $50.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
44.50x
P/B ratio:
4.50x
Volume:
499K
Avg. volume:
1.1M
1-year change:
-22.13%
Market cap:
$873M
Revenue:
--
EPS (TTM):
-$2.11
Analysts' Opinion
-
Consensus RatingLENZ Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $53.50, LENZ Therapeutics, Inc. has an estimated upside of 91.76% from its current price of $27.90.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing -29.03% downside risk from its current price of $27.90.
Fair Value
-
According to the consensus of 6 analysts, LENZ Therapeutics, Inc. has 91.76% upside to fair value with a price target of $53.50 per share.
LENZ vs. S&P 500
-
Over the past 5 trading days, LENZ Therapeutics, Inc. has underperformed the S&P 500 by -9.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
LENZ Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
LENZ Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter LENZ Therapeutics, Inc. reported revenues of $12.5M.
Earnings Growth
-
LENZ Therapeutics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter LENZ Therapeutics, Inc. reported earnings per share of -$0.59.
Enterprise value:
671.8M
EV / Invested capital:
3.45x
Price / LTM sales:
44.50x
EV / EBIT:
--
EV / Revenue:
38.39x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-14.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$17.3M
Return On Assets:
-27.55%
Net Income Margin (TTM):
-336.47%
Return On Equity:
-29.1%
Return On Invested Capital:
-28.93%
Operating Margin:
-151.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $17.5M | -- | $12.5M | |
| Gross Profit | -$2.2M | -$37K | $17.3M | -$10K | $12.4M | |
| Operating Income | -$74.2M | -$68.4M | -$67.9M | -$12.9M | -$18.9M | |
| EBITDA | -$72M | -$68.3M | -$67.7M | -$12.9M | -$18.8M | |
| Diluted EPS | -$26.74 | -$88.60 | -$2.11 | -$0.38 | -$0.59 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $401.2M | $298.5M | $238.8M | $220.7M | $207M | |
| Total Assets | $416.2M | $334.8M | $266.2M | $224M | $210.7M | |
| Current Liabilities | $11.3M | $13.5M | $12.5M | $7.7M | $16.3M | |
| Total Liabilities | $16M | $18.4M | $62.2M | $8.7M | $16.8M | |
| Total Equity | $400.1M | $316.5M | $204M | $215.3M | $193.9M | |
| Total Debt | $9.5M | $2.5M | $49.7M | $953K | $461K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$61.8M | -- | -$45.2M | -$10.6M | -$8.6M | |
| Cash From Investing | -$31.3M | -- | $2.3M | -$62.2M | -$4.3M | |
| Cash From Financing | $82.9M | -- | $27.2M | $29.8M | $598K | |
| Free Cash Flow | -$62.9M | -- | -$46.2M | -$10.8M | -$9M | |
LENZ
Sector
Market Cap
$873M
$28.4M
Price % of 52-Week High
55.36%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-2.03%
-1.32%
1-Year Price Total Return
-22.13%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$29.58
200-day SMA
Sell
Level
$31.15
Bollinger Bands (100)
Sell
Level
28.88 - 41.96
Chaikin Money Flow
Sell
Level
-7.2M
20-day SMA
Buy
Level
$27.42
Relative Strength Index (RSI14)
Sell
Level
44.79
ADX Line
Sell
Level
21.83
Williams %R
Neutral
Level
-59.3268
50-day SMA
Sell
Level
$33.78
MACD (12, 26)
Sell
Level
-0.80
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (41.7661)
Sell
CA Score
(Annual)
Level (-0.5169)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (6.3972)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.
Stock Forecast FAQ
In the current month, LENZ has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LENZ average analyst price target in the past 3 months is $53.50.
-
Where Will LENZ Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that LENZ Therapeutics, Inc. share price will rise to $53.50 per share over the next 12 months.
-
What Do Analysts Say About LENZ Therapeutics, Inc.?
Analysts are divided on their view about LENZ Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LENZ Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is LENZ Therapeutics, Inc.'s Price Target?
The price target for LENZ Therapeutics, Inc. over the next 1-year time period is forecast to be $53.50 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LENZ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for LENZ Therapeutics, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LENZ?
You can purchase shares of LENZ Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LENZ Therapeutics, Inc. shares.
-
What Is The LENZ Therapeutics, Inc. Share Price Today?
LENZ Therapeutics, Inc. was last trading at $27.85 per share. This represents the most recent stock quote for LENZ Therapeutics, Inc.. Yesterday, LENZ Therapeutics, Inc. closed at $27.90 per share.
-
How To Buy LENZ Therapeutics, Inc. Stock Online?
In order to purchase LENZ Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get LENZ Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LENZ
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
4.50x
1.84x
Price / LTM sales
44.50x
1.60x
Growth Metrics
LENZ
Sector
Revenue growth
--
4.85%
Earnings growth
-55.65%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.69
-$0.20
Profitability
LENZ
Sector
Profitability FY 2024
-$58K
$3.6M
Return on invested capital
-28.93%
-30.98%
Return on assets
-27.55%
-27.62%
Return on equity
-29.1%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
18
Estimated Next Earnings Date
Feb
4
Balance Sheet
LENZ
Sector
Total cash
$202.2M
$27.2M
Short term investments
$188.9M
$25.7M
Total assets
$215.3M
$79.9M
Long term debt
$461K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
